Veeda Clinical Research
Generated 5/25/2026
Executive Summary
Veeda Clinical Research is a clinical research organization (CRO) headquartered in Ahmedabad, India, that provides comprehensive clinical trial services to pharmaceutical, biotechnology, and medical device companies. Founded in 2020, the company specializes in diagnostics and offers integrated clinical trial management platforms and diagnostic validation methodologies across all phases of clinical development, from early-stage to post-marketing studies. With a focus on oncology, infectious diseases, and cardiology, Veeda serves a growing demand for outsourcing clinical trials in emerging markets. The company employs 200-500 staff and operates as a private platform-stage firm, leveraging cost-effective operations and a skilled workforce to compete with larger global CROs. Veeda's integrated technology approach aims to streamline trial processes, reduce timelines, and enhance data quality for sponsors. As India's clinical research sector expands, Veeda is well-positioned to capture market share through its specialized diagnostic services and flexible project management. The company's estimated valuation and total raised are not disclosed, but its private status suggests a focus on organic growth or targeted funding rounds. Key drivers include increasing R&D outsourcing by pharma firms, a favorable regulatory environment in India, and the rising complexity of clinical trials requiring specialized diagnostic support. Veeda's ability to maintain regulatory compliance and adopt novel technologies will be critical for sustained growth. The company faces competition from established CROs but differentiates through its diagnostic-focused offerings and local expertise in infectious diseases and oncology.
Upcoming Catalysts (preview)
- Q3 2026Expansion of US or European operations through partnerships or new offices60% success
- Q4 2026Launch of a proprietary digital clinical trial management platform50% success
- Q2 2026Major contract win with a top-20 pharmaceutical company40% success
- · Pipeline Analysis
- · Competitive Landscape
- · Catalyst Calendar (full 12-month)
- · Bull Case
- · Bear Case
- · Counterfactual Scenarios
- · Valuation Notes
- · SEC Filing Highlights
- · Insider Activity
- · Literature Watch
- · Patent Landscape
- · Mechanism Cluster Map
- · Audio Briefing (5 min)